Ironwood Pharmaceuticals appoints Tammi Gaskins as CEO, Tom McCourt to retire
Ironwood Pharmaceuticals announced that its board has appointed Chief Commercial Officer Tammi Gaskins as chief executive officer effective January 1, 2027. Current CEO Tom McCourt will retire on that date but will remain a member of the board. Gaskins, who joined the company in 2020 and led the commercial success of LINZESS and the apraglutide program, will also join the board, expanding it to nine directors.
Why it matters
The leadership transition provides continuity after a turnaround year and may influence the company’s commercial strategy for LINZESS and the late‑stage apraglutide pipeline. Investors will watch how the new CEO’s experience shapes future growth and board dynamics.
Key facts
- 1Tammi Gaskins will become CEO and a board member effective January 1, 2027. stocktitan.net
- 2Tom McCourt will retire as CEO on January 1, 2027 but will stay on the board. tradingview.com
- 3Gaskins joined Ironwood in 2020 and has led the commercial organization, including LINZESS and apraglutide. investing.com
- 4The board will increase to nine members after Gaskins joins. tradingview.com
Summary written by AlphAI AI Desk from 5 of 5 sources. Not investment advice. Figures are as stated by the linked sources.